These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 14615472)
1. Pharmacokinetics of E5564, a lipopolysaccharide antagonist, in patients with impaired hepatic function. Liang E; Wong YN; Allen I; Kao R; Marino M; DiLea C J Clin Pharmacol; 2003 Dec; 43(12):1361-9. PubMed ID: 14615472 [TBL] [Abstract][Full Text] [Related]
2. Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers. Rossignol DP; Wong N; Noveck R; Lynn M Innate Immun; 2008 Dec; 14(6):383-94. PubMed ID: 19039062 [TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study. Wong YN; Rossignol D; Rose JR; Kao R; Carter A; Lynn M J Clin Pharmacol; 2003 Jul; 43(7):735-42. PubMed ID: 12856387 [TBL] [Abstract][Full Text] [Related]
4. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. Lynn M; Rossignol DP; Wheeler JL; Kao RJ; Perdomo CA; Noveck R; Vargas R; D'Angelo T; Gotzkowsky S; McMahon FG J Infect Dis; 2003 Feb; 187(4):631-9. PubMed ID: 12599080 [TBL] [Abstract][Full Text] [Related]
5. Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers. Rossignol DP; Wasan KM; Choo E; Yau E; Wong N; Rose J; Moran J; Lynn M Antimicrob Agents Chemother; 2004 Sep; 48(9):3233-40. PubMed ID: 15328078 [TBL] [Abstract][Full Text] [Related]
6. LPS binding protein does not participate in the pharmacokinetics of E5564. Kaneko K; Ueda R; Kawata T; Ishizaka S; Yoshimura T J Endotoxin Res; 2004; 10(3):185-94. PubMed ID: 15198853 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. Zhao RK; Cheng G; Tang J; Song J; Peng WX Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103 [TBL] [Abstract][Full Text] [Related]
8. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. Rossignol DP; Lynn M J Endotoxin Res; 2002; 8(6):483-8. PubMed ID: 12697095 [TBL] [Abstract][Full Text] [Related]
9. Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]. Lynn M; Wong YN; Wheeler JL; Kao RJ; Perdomo CA; Noveck R; Vargas R; D'Angelo T; Gotzkowsky S; McMahon FG; Wasan KM; Rossignol DP J Pharmacol Exp Ther; 2004 Jan; 308(1):175-81. PubMed ID: 14566003 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of iloprost in patients with hepatic dysfunction. Hildebrand M; Krause W; Angeli P; Koziol T; Gatta A; Merkel C; Bolognesi M Int J Clin Pharmacol Ther Toxicol; 1990 Oct; 28(10):430-4. PubMed ID: 1701761 [TBL] [Abstract][Full Text] [Related]
11. Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function. Valles J; Artigas R; Bertolotti M; Crea A; Muller F; Paredes I; Capriati A Methods Find Exp Clin Pharmacol; 2006 Jun; 28 Suppl A():29-36. PubMed ID: 16801990 [TBL] [Abstract][Full Text] [Related]
12. Disposition of a synthetic analogue of lipid A (E5564) in rats. Kaneko K; Ueda R; Nemoto H; Iijima H; Yoshimura T Xenobiotica; 2003 Mar; 33(3):323-39. PubMed ID: 12637248 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction. Baur M; Drescher A; Gneist M; Dittrich C; Jaehde U Cancer Chemother Pharmacol; 2008 Jan; 61(1):97-104. PubMed ID: 17396265 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease. Smith WB; Dowell JA; Pratt RD Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688 [TBL] [Abstract][Full Text] [Related]
15. E5564 (Eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes. Czeslick E; Struppert A; Simm A; Sablotzki A Inflamm Res; 2006 Nov; 55(11):511-5. PubMed ID: 17122970 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of ciprofloxacin in impaired liver function. Esposito S; Miniero M; Barba D; Sagnelli E Int J Clin Pharmacol Res; 1989; 9(1):37-41. PubMed ID: 2707924 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment. Puttonen J; Kantele S; Ruck A; Ramela M; Häkkinen S; Kivikko M; Pentikäinen PJ J Clin Pharmacol; 2008 Apr; 48(4):445-54. PubMed ID: 18303124 [TBL] [Abstract][Full Text] [Related]
18. A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment. Bramson C; Ouellet D; Roman D; Randinitis E; Gardner MJ J Clin Pharmacol; 2006 Jan; 46(1):29-36. PubMed ID: 16397281 [TBL] [Abstract][Full Text] [Related]
19. Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment. Barth J; Jäger D; Mundkowski R; Drewelow B; Welte T; Burkhardt O J Antimicrob Chemother; 2008 Sep; 62(3):575-8. PubMed ID: 18515790 [TBL] [Abstract][Full Text] [Related]
20. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis. De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]